Mizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19

Benzinga Newsdesk www.benzinga.com Positive 92.8%

Neg 0% Neu 0% Pos 92.8%

Mizuho analyst Uy Ear maintains Relmada Therapeutics (NASDAQ:RLMD) with a Outperform and raises the price target from $10 to $19.